Literature DB >> 25680863

Targeting angiogenesis in head and neck cancer.

Maria Vassilakopoulou1, Amanda Psyrri2, Athanassios Argiris3.   

Abstract

Angiogenesis is a crucial step in tumor growth and metastasis. Head and neck squamous cell carcinomas (HNSCC) highly express angiogenesis factors, such as vascular endothelial growth factor (VEGF), which are associated with patient prognosis. Antiangiogenesis agents can potentially modulate tumor microenvironment and induce radiosensitivity and chemosensitivity. In this review, we discuss the molecular mechanisms underlying angiogenesis involved in HNSCC, preclinical data with antiangiogenesis agents as well as potential predictive biomarkers. We also review novel therapies under investigation and summarize the results of clinical trials using antiangiogenesis agents alone or in combination with conventional therapies in HNSCC.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Bevacizumab; Head and neck cancer; Monoclonal antibodies; Targeted therapy; Tyrosine kinase inhibitors; Vascular endothelial growth factor; Vascular endothelial growth factor receptor

Mesh：

Year:  2015        PMID： 25680863     DOI： 10.1016/j.oraloncology.2015.01.006

Source DB:  PubMed          Journal:  Oral Oncol        ISSN： 1368-8375            Impact factor:   5.337


  22 in total

1.  Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.

Authors:  Athanassios Argiris; Shuli Li; Panayiotis Savvides; James P Ohr; Jill Gilbert; Marshall A Levine; Arnab Chakravarti; Missak Haigentz; Nabil F Saba; Chukwuemeka V Ikpeazu; Charles J Schneider; Harlan A Pinto; Arlene A Forastiere; Barbara Burtness
Journal:  J Clin Oncol       Date:  2019-10-16       Impact factor: 44.544

2.  RGD-K5 PET/CT in patients with advanced head and neck cancer treated with concurrent chemoradiotherapy: Results from a pilot study.

Authors:  Shih-Hsin Chen; Hung-Ming Wang; Chien-Yu Lin; Joseph Tung-Chieh Chang; Chia-Hsun Hsieh; Chun-Ta Liao; Chung-Jan Kang; Lan-Yan Yang; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-27       Impact factor: 9.236

3.  Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model: A preliminary study.

Authors:  Hisato Yoshida; Hitoshi Yoshimura; Shinpei Matsuda; Takashi Ryoke; Tamotsu Kiyoshima; Motohiro Kobayashi; Kazuo Sano
Journal:  Oncol Lett       Date:  2018-03-30       Impact factor: 2.967

Review 4.  [PET-CT in head and neck cancer].

Authors:  T Send; B Kreppel; F C Gaertner; R A Bundschuh; H Strunk; F Bootz; M Essler
Journal:  HNO       Date:  2017-06       Impact factor: 1.284

Review 5.  Precision Therapy of Head and Neck Squamous Cell Carcinoma.

Authors:  P J Polverini; N J D'Silva; Y L Lei
Journal:  J Dent Res       Date:  2018-04-12       Impact factor: 6.116

6.  A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Authors:  Antonio Jimeno; Marshall R Posner; Lori J Wirth; Nabil F Saba; Roger B Cohen; Elizabeta C Popa; Athanassios Argiris; Kenneth F Grossmann; Ammar Sukari; Dawn Wilson; Xiaosha Zhang; Jade Sun; Chad Glasser; Kenneth M Attie; Matthew L Sherman; Susan S Pandya; Jared Weiss
Journal:  Cancer       Date:  2016-09-20       Impact factor: 6.860

Review 7.  Cancer therapy and cardiovascular risk: focus on bevacizumab.

Authors:  Panagiota Economopoulou; Athanasios Kotsakis; Ioannis Kapiris; Nikolaos Kentepozidis
Journal:  Cancer Manag Res       Date:  2015-06-03       Impact factor: 3.989

Review 8.  Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC).

Authors:  María José Echarri; Ana Lopez-Martin; Ricardo Hitt
Journal:  Cancers (Basel)       Date:  2016-02-26       Impact factor: 6.639

9.  Androgen receptor (AR) signaling promotes RCC progression via increased endothelial cell proliferation and recruitment by modulating AKT → NF-κB → CXCL5 signaling.

Authors:  Zhenfeng Guan; Chong Li; Jinhai Fan; Dalin He; Lei Li
Journal:  Sci Rep       Date:  2016-11-16       Impact factor: 4.379

10.  Survivin expression, HPV positivity and microvessel density in oropharyngeal carcinomas and relationship with survival time.

Authors:  Ebru Tastekin; Vuslat Yurut Caloglu; Nilufer Kilic Durankus; Necdet Sut; Gorkem Turkkan; Nuray Can; Fulya Oz Puyan; Murat Caloglu
Journal:  Arch Med Sci       Date:  2016-04-27       Impact factor: 3.318
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.